Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial
Jun Liang,Nan Bi,S. Wu,Ming Chen,C. Lv,L. Zhao,A. Shi,Wei Jiang,Yaomin Xu,Zongmei Zhou,Wei Wang,Dongfu Chen,Zhouguang Hui,J. Lv,Hongxing Zhang,Qinfu Feng,Zefen Xiao,Xin Wang,Lipin Liu,Tao Zhang,Liping Du,Wei Chen,Yu Shyr,Weibo Yin,Jian Li,Jie He,Luhua Wang +26 more
TLDR
EP might be superior to weekly PC in terms of OS in the setting of concurrent chemoradiation for unresectable stage III NSCLC.About:
This article is published in Annals of Oncology.The article was published on 2017-04-01 and is currently open access. It has received 141 citations till now. The article focuses on the topics: Carboplatin & Etoposide.read more
Citations
More filters
Journal ArticleDOI
Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Yun Chen,Jinjun Ye,Zhengfei Zhu,Weixin Zhao,Jialiang Zhou,Chaoyang Wu,Huarong Tang,Min Fan,Ling Li,Qin Lin,Yi Xia,Yunhai Li,Jiancheng Li,Huixun Jia,Saiquan Lu,Zhen Zhang,Kuaile Zhao +16 more
TL;DR: The paclitaxel plus fluorouracil regimen did not significantly prolong the OS compared with the standard cisplatin plus fluorourspectrum regimen in dCRT in patients with locally advanced ESCC.
Journal ArticleDOI
Lung Cancer in People's Republic of China.
Journal ArticleDOI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Kwang Bo Park,Johan Vansteenkiste,Ki Hyeong Lee,Georgios Pentheroudakis,C. Zhou,Kumar Prabhash,Takashi Seto,P.J. Voon,D.S.W. Tan,J.C.-H. Yang,Jinwan Wang,K Govind Babu,Y. Nakayama,Adlinda Alip,K.L.M. Chua,Jason Chia-Hsien Cheng,Suresh Senan,Yong Chan Ahn,Tae Yong Kim,Hee Kyung Ahn,Solange Peters,Takayuki Yoshino,J.-Y. Douillard +22 more
TL;DR: These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
Journal ArticleDOI
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
TL;DR: In this paper , an Expert Panel of medical oncology, thoracic surgery, radiation oncologists, lung cancer, community oncologist, research methodology, and advocacy experts was convened to conduct a literature search, which included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021.
Journal ArticleDOI
Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC.
Nikhil Yegya-Raman,Kyle Wang,Sinae Kim,Meral Reyhan,Matthew P. Deek,Mutlay Sayan,Diana Li,Malini Patel,Jyoti Malhotra,Joseph Aisner,Lawrence B. Marks,Salma K. Jabbour +11 more
TL;DR: In this paper, the authors retrospectively reviewed the records of 140 patients with inoperable NSCLC treated with concurrent chemoradiation therapy (CRT) from 2007 to 2015.
References
More filters
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal ArticleDOI
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
TL;DR: Overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer was compared.
Journal ArticleDOI
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more
TL;DR: Concomitant radiochemotherapy, as compared with sequential radiochemicalotherapy, improved survival of patients with locally advanced NSCLC, primarily because of a better locoregional control, but at the cost of manageable increased acute esophageal toxicity.
Journal ArticleDOI
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
Andrea Ardizzoni,Luca Boni,Marcello Tiseo,Frank V. Fossella,Joan H. Schiller,Marianne Paesmans,Davorin Radosavljevic,Adriano Paccagnella,Petr Zatloukal,Paola Mazzanti,Donald Bisset,Rafael Rosell +11 more
TL;DR: Cisplatin-based third-generation regimens should remain the standard reference for the treatment of selected patients with advanced-stage NSCLC and of those with earlier-stage disease.
Journal ArticleDOI
Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
Karen Kelly,Kari Chansky,Laurie E. Gaspar,Kathy S. Albain,James R. Jett,Yee C. Ung,Derick H Lau,John Crowley,David R. Gandara +8 more
TL;DR: In this unselected population of patients with advanced non-small-cell lung cancer, gefitinib did not improve survival, and decreased survival was a result of tumor progression and not gefithinib toxicity.
Related Papers (5)
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
Jeffrey D. Bradley,Rebecca Paulus,Ritsuko Komaki,Gregory A. Masters,George R. Blumenschein,Steven E. Schild,Jeffrey A. Bogart,Chen Hu,Kenneth M. Forster,Anthony M. Magliocco,V.S. Kavadi,Yolanda I. Garces,Samir Narayan,Puneeth Iyengar,Cliff G. Robinson,Raymond B. Wynn,Christopher Koprowski,Joanne Meng,Jonathan J. Beitler,Rakesh Gaur,Walter J. Curran,Hak Choy +21 more
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takashi Yokoi,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Catherine Wadsworth,Giovanni Melillo,Haiyi Jiang,Y. Huang,Phillip A. Dennis,Mustafa Ozguroglu,Pacific Investigators +30 more
Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia,A. Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,A. Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Cheol Cho,M. Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young-Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz-Ares,Javier de Castro Carpeño,Corinne Faivre-Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Ozguroglu +32 more